Rapid In Vivo Antibody Discovery

Accelerating Biotherapeutics With Innovation

BinderGenᵀᴹ Antibody Discovery Platform

We’ve taken a tried-and-true monoclonal antibody discovery technology and made it better and faster.
What traditionally takes 3 to 6 months, we achieve in 6 weeks.

Our Mission

Our mission is to accelerate the discovery and development of immunotherapeutics. Our BinderGenᵀᴹ lead discovery platform generates diverse in vivo-matured monoclonal antibody target binders in 6 weeks designed to empower downstream preclinical drug development applications including target validation, proof-of-concept, lead optimization, multimodality engineering, and AI/ML datasets.

The Immunovive team brings decades of expertise, innovation, and leadership that has delivered success to thousands of biotherapeutic investigators worldwide. As a strictly fee-for-service preclinical CRO committed to mobilizing therapeutic ideas to proof-of-concept all rights to the resultant antibodies are 100% retained by the client.

Our Team

Devin E. Turner, Ph.D.
Founder and CEO

Devin Turner

Devin E. Turner, Ph.D., Founder and CEO

Devin Turner is the founder of Abveris Antibody and creator of DiversimAbTM and BinderGenTM antibody discovery technologies. In six years without investment, Devin led Abveris through substantial growth, technological innovation, a successful exit and fulfilling its mission to deliver scores of biotherapeutic lead molecules to drug hunters. More recently, Devin was the Head of Antibody Discovery Services at Alloy Therapeutics, where he led a world-class multidisciplinary team generating fully human antibody-based therapeutics from Alloy’s state-of-the-art suite of humanized mice. Devin continues his passion for immunotherapeutics through his latest company, Immunovive, a Boston-based CRO accelerating biologics discovery with its robust in vivo-based antibody hit generation platform, BinderGenTM, delivering diverse panels of high affinity monoclonal hybridomas in just 6 weeks. When not immersed in science, Devin enjoys BBQing, hiking, biking, boating, and being the best dad ever. Devin earned his B.S. in Molecular, Cellular, and Developmental Biology from UCLA and his Ph.D. in Immunology from Harvard Medical School.

Rashed Abdullah, Ph.D., PMP
Associate Director of Operations and Business Development

Rashed Abdullah

Rashed Abdullah, Ph.D., PMP, Associate Director of Operations and Business Development

Dr. Rashed Abdullah is a seasoned scientist with over two decades of experience in therapeutic antibody discovery, oncology, vaccine development, and neurodegenerative disease research. A certified Project Management Professional (PMP), he has led R&D programs and cross-functional teams across biotech and CRO environments. His expertise spans monoclonal and polyclonal antibody development, AOC/ADC platforms, assay design, and preclinical strategy. Dr. Abdullah has held leadership roles at Gennao Bio, Abveris (now Twist Bio), and Immunovive LLC, where he currently serves as Associate Director of Operations and Business Development. He holds a Ph.D. in Biology from St. John's University and has contributed to numerous peer-reviewed publications in the field of therapeutic discovery.

Tom Daly, Jr.

Tom Daly, Jr., M.Sc., Scientist

Tom has over 17 years combined experience in drug discovery, particularly using in vivo models in disease areas of cancer and autoimmune diseases. Throughout his career he has dedicated his efforts to discover and develop drug therapies such as Necuparanib, which reached Phase II; CTX-471, currently in Phase I clinical trials; and others that are still in preclinical stage development. He was also on the initial development team for Nipoclamib, an anti-FcRn approved by the FDA in April 2025. Tom has developed tumor, platelet depletion, and rescue in vivo models, as well as other pharmacokinetic models. Most recently at Alloy Therapeutics and now here at Immunovive, he has specialized in the generation of monoclonal hybridoma colonies from mouse B cells that generate target specific antibodies for customer projects and is dedicated to the delivery of a potential drug target for clients. He earned his Masters Degree in Biotechnology from Worcester State University.

Contact Us

Accelerate Your Discovery!

Contact Devin Directly

devin@immunovivellc.com